Biotie Therapies

Acorda Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Thursday, March 9, 2023

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today reported its financial results for the fourth quarter and full year ended December 31, 2022.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today reported its financial results for the fourth quarter and full year ended December 31, 2022.
  • “Acorda’s operating and financial performance improved throughout the year, meeting our financial guidance for 2022 AMPYRA net revenue, INBRIJA U.S. net revenue, cash, and adjusted OPEX.
  • For the quarter ended December 31, 2022, the Company reported AMPYRA net revenue of $18.8 million, a 16.6% decrease compared to the same quarter in 2021.
  • Additionally, for the quarter ended December 31, 2022, the Company reported FAMPYRA royalty revenues of $2.7 million, a 25.1% decrease compared to the same quarter in 2021.

Acorda Therapeutics Announces Revised Long-Term Financial Guidance

Retrieved on: 
Thursday, December 22, 2022

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has revised and updated the long-term financial guidance most recently included in its November 1, 2022 press release announcing its financial results for the third quarter of 2022.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has revised and updated the long-term financial guidance most recently included in its November 1, 2022 press release announcing its financial results for the third quarter of 2022.
  • The revised guidance also reflects updates from actual financial results from October and November 2022 and from the Company’s year-end budgeting process.
  • The revised long-term financial guidance does not affect Acorda’s previously reported financial results for the period ended September 30, 2022 or Inbrija U.S. net revenue guidance for 2022 of between $27.8 - $28.7 million.
  • This will have no impact on the financial guidance below, which does not reference net income, and will be reflected in the Company’s annual audited financial statements.

Acorda Therapeutics Reports First Quarter 2022 Financial Results

Retrieved on: 
Wednesday, May 11, 2022

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a business update and reported its financial results for the first quarter ended March 31, 2022.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a business update and reported its financial results for the first quarter ended March 31, 2022.
  • For the quarter ended March 31, 2022, the Company reported INBRIJA net revenue of $3.7 million, compared to $5.0 million for the same quarter in 2021.
  • Change in fair value of derivative liability for the quarter ended March 31, 2022 was negligible, compared to $0.2 million for the same quarter in 2021.
  • A reconciliation of the GAAP financial results to non-GAAP financial results is included with the attached financial statements.

BioAge appoints Dov Goldstein as Chief Financial Officer and Ann Neale as Chief Development Officer

Retrieved on: 
Wednesday, November 17, 2021

BioAge Labs, Inc., a clinical-stage biotechnology company developing medications that target the molecular causes of aging to extend healthy human lifespan, today announced the appointment of Dov Goldstein, M.D., M.B.A. as Chief Financial Officer (CFO) and Ann Neale as Chief Development Officer (CDO).

Key Points: 
  • BioAge Labs, Inc., a clinical-stage biotechnology company developing medications that target the molecular causes of aging to extend healthy human lifespan, today announced the appointment of Dov Goldstein, M.D., M.B.A. as Chief Financial Officer (CFO) and Ann Neale as Chief Development Officer (CDO).
  • We are thrilled to welcome two seasoned industry leaders into the BioAge management team, said Kristen Fortney, Ph.D., CEO of BioAge.
  • Goldstein comes to BioAge with extensive strategic financial experience in the biopharmaceutical sector.
  • He joins BioAge from Indapta Therapeutics, where he served as chief financial and business officer from 2020 to 2021 and was responsible for the companys growth strategies as well as operational finance and business development.

Global Juvenile Idiopathic Arthritis Clinical Trial Pipeline Research Report 2021-2025: Phase 3, Phase 2, Phase 1, Preclinical Research, and Discovery Stage - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 21, 2021

The "Global Juvenile Idiopathic Arthritis Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Juvenile Idiopathic Arthritis Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Juvenile Idiopathic Arthritis Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Juvenile Idiopathic Arthritis market.
  • It covers emerging therapies for Juvenile Idiopathic Arthritis in active clinical development stages including early and late stage clinical trials.
  • The report provides Juvenile Idiopathic Arthritis pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Global Gout Clinical Trial Pipeline Market research Report 2021: Phase 3, Phase 2, Phase 1, Preclinical Research, and Discovery Stage - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 21, 2021

The "Global Gout Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Gout Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Gout Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Gout market.
  • It covers emerging therapies for Gout in active clinical development stages including early and late stage clinical trials.
  • The report provides Gout pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Global Celiac Disease Clinical Trial Pipeline Report 2021-2025: Phase 3, Phase 2, Phase 1, Preclinical Research, and Discovery Stage - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 21, 2021

The "Global Celiac Disease Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Celiac Disease Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Celiac Disease Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Celiac Disease market.
  • It covers emerging therapies for Celiac Disease in active clinical development stages including early and late stage clinical trials.
  • The report provides Celiac Disease pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Global Graft Vs Host Disease Clinical Trial Pipeline Research Report 2021: Phase 3, Phase 2, Phase 1, Preclinical Research, and Discovery Stage - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 21, 2021

The "Global Graft Vs Host Disease Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Graft Vs Host Disease Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Graft Vs Host Disease Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Graft Vs Host Disease market.
  • It covers emerging therapies for Graft Vs Host Disease in active clinical development stages including early and late stage clinical trials.
  • The report provides Graft Vs Host Disease pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

vTv Therapeutics to Participate at the 6th World Psoriasis & Psoriatic Arthritis Conference with Poster Presentation on HPP737

Retrieved on: 
Tuesday, June 29, 2021

The poster will be added to vTvs website following the presentation and will be available at: https://vtvtherapeutics.com/pipeline/hpp737/ .

Key Points: 
  • The poster will be added to vTvs website following the presentation and will be available at: https://vtvtherapeutics.com/pipeline/hpp737/ .
  • HPP737 is a novel, potent, orally administered PDE4 inhibitor discovered by vTv Therapeutics.
  • PDE4 is a validated therapeutic target for the treatment of a variety of disorders including psoriasis.
  • vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes (T1D) and psoriasis.

Global Cocaine Addiction Clinical Trial Pipeline Highlights Report 2021: Clinical trial Stages, Drug Mechanism Classes, Competitive Landscape, Short-term Launch Highlights - ResearchAndMarkets.com

Retrieved on: 
Friday, March 19, 2021

The "Global Cocaine Addiction Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cocaine Addiction Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Cocaine Addiction Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Cocaine Addiction market.
  • It covers emerging therapies for Cocaine Addiction in active clinical development stages including early and late stage clinical trials.
  • The report provides Cocaine Addiction pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.